molecules of the month

compound 1

CD33 splicing modulator

preclinical (neurodegeneration)

from 3.1M cmpd phenotypic CD33 splicing screen

ACS Med. Chem. Lett.

Pfizer Inc.

CD33 splicing modulator - Pfizer Inc.
1 min read

compound 1 is a CD33 pre-mRNA splicing modulator that increases CD33 exon 2 skipping in cells. CD33/Siglec 3 regulates microglia activity, and genetic alterations of CD33 are associated with protection from Alzheimer’s. Alternative splicing of CD33 with exclusion of exon 2 is hypothesized to copy the protective effect of the human genetic variants. The hit is an interesting proof-of-concept for pre-mRNA splicing manipulation by a small molecule. It was identified from an HTS of the full Pfizer library of 3.1M compounds, using a reporter-gene-based phenotypic CD33 splicing assay. The hit was derived from a previous PCSK9 translational stalling project. A high-content imaging assay for cytotoxicity was used to qualify hits. Unfortunately, despite promising initial SAR, the program was discontinued and…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: